Denna webbplats använder teknik som troligen inte stöds i din webbläsare, därför kan vissa saker se konstiga ut eller inte fungera. Vi rekommenderar att du byter till en modern webbläsare istället.
Gå direkt till huvudinnehållet

Novel tools to study impact of gut x microbiota interactions for development of colorectal cancer

MoRE2020 Fellow Kati Hanhineva incoming mobility from University of Eastern Finland to Chalmers University of Technology

Project summary

The human gut microbiota has been shown to play a key role in human health. Most studies investigated the gut microbiota compoisition using 16SrRNA-technology or shot-gun metagenomics. These techniques require acces to fecal samples and may be costly and complex (shot-gun metagenomics). Recent data has shown that the fecal metabolome, i.e. the comprehensive pool of small molecules, to a large extent reflects the gut microbiota
composition and that it could be used as a complementary functional readout of microbioal metabolism and its interactions with enviromental factors such as the diet and with the host. Moreover, fecal metabolomics has been shown to overalp well with the plasma metabolome, i.e. large number of gut microbiota x host x diet derived metabolites can be detected in plasma. Methods and infrastructures to analyse fecal metabolites at large scale are
currenrlt lacking as well as plasma biomarkers that reflect gut microbiota activities in interaction with dietary components. Such plasma biomarkers could be used to study the role of gut microbiota and diet in chronic dieases such as colorectal cancer, by using data and sampels from large prospective cohort studies, where fecal samples are typically not available. The overall aim of this project is to establish a high-throughput pipeline for targeted and
untargeted fecal metabolomics to develop and validate specific biomarkers of gut microbiota and diet interactions to be linked with our recently established untargeted plasma metabolomics platform. This combined fecal/plasma pipeline will be used to identify and validate novel fecal and blood-based biomarkers of GI microbiota for highthroughput
analysis of large-scale cohort material for use in epidemiological research linking microbiota to health and disease and revealing underlying mechanisms. Specifically, we will test wherther derived gut microbiota x diet interaction biomarkers in plasma affects the risk of developing colorectal cancer, using data and samples from existing Swedish and Danish prospective cohorts. The current project will provide a powerful addition to our current
metabolomics platform at Chalmers to investigate the role of fut microbiota and diet on health outcomes, such as colorectal cancer as well bringing together research project on gut microbiota and health in the Gothenburg area.

Collaborating end-users: Biobank Väst

Senast uppdaterad: 2019-03-21 13:03